The Type 1 diabetes clinical research team at Indiana University School of Medicine is working to advance detection and treatment for people at all stages of diabetes development and progression.
The three main goals of the research team are to prevent disease development in people who are high risk, preserve beta cell function in newly diagnosed patients, and improve quality of life through technology and therapeutics in persons with established diabetes.
Learn more about the focus and phases of clinical research and explore additional active studies conducted by IU School of Medicine physician investigators.
Currently, the clinical research team is conducting studies involving people who have a high risk for Type 1 diabetes, patients with newly diagnosed Type 1 diabetes and people with established Type 1 diabetes.
Questions or requests for additional information may be directed via email to a study coordinator.
Study coordinator: Angelica McKibben, atmckibb@iu.edu
Open for enrollment: Yes
The purpose of this study is to evaluate the safety and tolerability of teplizumab treatment in participants with Stage 2 Type 1 diabetes who are less than 8 years of age.
Study coordinator: Riley Pediatric Diabetes Research Team, pedsdiab@iu.edu
Open for enrollment: Yes
The purpose of this observational study is to detect Type 1 diabetes at its earliest stages. Family members of people with Type 1 diabetes are screened for autoantibodies associated with Type 1 diabetes development.
T1D is characterized by the autoimmune destruction of insulin-producing pancreatic β-cells. The purpose of this study is to examine the broad range of pancreas sizes in those with T1D risk to evaluate if a change from baseline over a defined time-period may provide the best sensitivity in estimating diabetes risk.
Study coordinator: Hannah Lease, hlease@iu.edu
Open for enrollment: Yes
The purpose of this study is to identify a safe, metabolically favorable, dosing regimen for a medicine siplizumab in patients with Type 1 diabetes that induces changes in T cell phenotypes observed with Type 1 diabetes.
The purpose of this study is to develop and validate biomarkers that predict T1D disease risk and document disease progression based on blood and urine indicators of beta cell stress and death in persons with emerging and established T1D.
Study coordinator: Ellie Moreau, elmryan@iu.edu
Open for enrollment: Yes
The purpose of this study is to investigate the potential of an oral medication difluoromethylornithine (DFMO) to alleviate stress on beta cells to preserve the body's intrinsic capacity to produce insulin following diagnosis.
Study coordinator: Angelica McKibben, atmckibb@iu.edu
Open for enrollment: Yes
The purpose of this study is to evaluate the use of rituximab-pvvr and abatacept, one after the other, to learn if using both treatments extends insulin production in people newly diagnosed with Type 1 diabetes.
With consent from participants the Type 1 diabetes Research Team collects and securely stores information to determine eligibility for future research studies. If a person in the database appears to meet criteria for inclusion in a future study, they can be contacted by the research team to see if they would like additional information about participating.
Study coordinator: Autumn Clark, autclark@iu.edu
Open for Enrollment: Yes
The purpose of this observational study is to profile the gut microbiome in youth with Type 1 diabetes according to weight categories and then determine if differences in the gut microbiome profile are associated with differences in measures of β-cell stress and death. Eligibility requirements: Youth 11-18 years of age with T1D at time of enrollment
